安进Amgen Inc. (AMGN) 2011年年度报告「NASDAQ」.pdf

1、Amgen 2011 Annual Report and Financial Summary40838_cvr.indd 140838_cvr.indd 13/15/12 9:01 AM3/15/12 9:01 AM*“Adjusted”earnings per share and“adjusted”R&D expenses are non-GAAP fi nancial measures.See page 12 for reconciliations to U.S.generally accepted accounting principles(GAAP).Our Mission:To Se

2、rve PatientsProductsAmgen ValuesAbout AmgenTotal revenues($in millions)2011$15,582 2010 15,053 2009 14,6422008 15,0032007 14,7710708091011“Adjusted”earnings per share(EPS)*07080910112011$5.332010 5.21 2009 4.91 2008 4.552007 4.2907080910112011$5,1192010 5,787 2009 6,336 2008 5,9882007 5,401Cash fl o

3、w from operations($in millions)“Adjusted”research and development(R&D)expenses*($in millions)07080910112011$3,1162010 2,7732009 2,739 2008 2,9102007 3,064Aranesp(darbepoetin alfa)Enbrel(etanercept)EPOGEN(epoetin alfa)Neulasta(pegfi lgrastim)NEUPOGEN(Filgrastim)Nplate(romiplostim)Prolia(denosumab)Sen

4、sipar/Mimpara(cinacalcet)Vectibix(panitumumab)XGEVA(denosumab)Be science-basedCompete intensely and winCreate value for patients,staff,and stockholdersBe ethicalTrust and respect each otherEnsure qualityWork in teamsCollaborate,communicate,and be accountableAmgen discovers,develops,manufactures,and

5、delivers innovative human therapeutics.A biotechnology pioneer since 1980,Amgen was one of the first companies to realize the new sciences promise by bringing safe,effective medicines from lab to manufacturing plant to patient.Amgen therapeutics have changed the practice of medicine,helping millions

6、 of people around the world in the fight against cancer,kidney disease,rheumatoid arthritis,bone disease,and other serious illnesses.With a deep and broad pipeline of potential new medicines,Amgen remains committed to advancing science to dramatically improve peoples lives.40838_cvr.indd 240838_cvr.